uniQure soars as it aligns regulatory path for Huntington’s candidate AMT-130
Dutch gene therapy company uniQure saw its shares rocket 86% to $13.57 today, after it reached agreement with the US Food and Drug Administration (FDA) on key elements of an Accelerated Approval pathway for AMT-130 in Huntington’s disease.
Hosted on MSN2d
uniQure Stock Hits 18-Month High After FDA Agreement Clears Pathway For Huntington’s Treatment: Retail Gets More OptimisticShares of gene therapy company uniQure more than doubled on Tuesday before trimming some gains, reaching their highest levels ...
The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...
Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...
In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified ...
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that ...
Qure stock surges after FDA agrees on an accelerated approval pathway for its Huntington's disease treatment, AMT-130.
In an update shared today, uniQure announced alignment with the US drug regulator on key criteria for accelerated approval of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback